Dambkowski Carl reported option exercise involving 4,125 derivative units of Apogee Therapeutics, Inc. at $0.00 for $0 on Jun 3, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Medical Officer
Chief Medical Officer
Filed Jun 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
4,125Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
118,915Direct
Trade date
Jun 3, 2026Option exercise
Filed
Jun 5, 2026, 8:00 PM ET3-day reporting delay
Accession
0001104659-26-071076Code M · Transaction 99768
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Jun 3, 2026Option exercise4,125$22.86$94,297.50Trade 99765
Jun 3, 2026Sell5,500$78.71−$432,905Trade 99767
3 transaction rows in this filing. Joint filers share the same rows.

APGE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
APGE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −3.9%1w ago −11%1d ago −9.5%
Returns since7d +1.6%30d +54%90d180d1y

Footnotes in full

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.